PARVG

Across TCGA pan-cancer cohorts, PARVG Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PARVG data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PARVG Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PARVG expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

HNSC, SARC, and PRAD are the cancer types where PARVG Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.222	0.742	.008	9	view →
SARC	DFS	Median	All	0.159	0.613	.015	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUAD	DFS	Median	All	1.000	0.328	.041	2	view →
COAD	DFS	Median	All	0.527	0.787	.025	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PARVG–HNSC (OS)

Open the HNSC breakdown →